Connect Biopharma Shares Plunge on Asthma Trial Failure

Key Facts

1Connect Biopharma shares dropped after its drug candidate rademikibart failed to meet primary endpoints in a Phase 2 trial for asthma.

In the high-stakes biotech sector where valuations hinge on clinical success, Connect Biopharma faced intense selling pressure. The company's shares dropped significantly following the announcement that its drug candidate rademikibart failed to meet primary endpoints in a Phase 2 trial for asthma. According to reports, the global trial did not achieve its predefined objectives, leading to an immediate revaluation of the firm's future potential.

This clinical failure underscores the inherent risks in drug development, as the setback of a key pipeline candidate often triggers a sharp decline in biotech valuations. Per market dynamics, the inability to reach clinical goals weakens future revenue projections and the company's standing within the competitive respiratory treatment market.

At the close on September 14, 2026, CNTB was priced at $1.73, having touched a session low of $1.58. With no immediate catalysts in the upcoming economic calendar related to the firm, investors will be watching for management updates regarding the future of the rademikibart program or potential pivots to other pipeline assets to recover lost value.